ライフサイエンスコーパス: leukotriene

1 alphaq and is unresponsive to stimulation by leukotriene.

2 macrophages gave higher levels of cysteinyl leukotrienes.

3 issues and excessive production of cysteinyl leukotrienes.

4 th enhanced production of prostaglandins and leukotrienes.

5 e responsiveness of human P2Y12 to cysteinyl leukotrienes.

6 shows similarity to the N-terminal domain of leukotriene A-4 hydrolase.

7 However, restoring the leukotriene A4 aminopeptidase activity with a pharmaceut

8 We hypothesized that the genotype of leukotriene A4 hydrolase (encoded by LTA4H), which deter

9 ted leukotriene B4 (LTB4) formation by human leukotriene A4 hydrolase (LTA4H) approximately 40% (P<0.

10 The enzyme leukotriene A4 hydrolase (LTA4H) catalyses the distal st

11 The leukotriene A4 hydrolase (LTA4H) is a bifunctional enzym

12 We investigated changes to the leukotriene A4 hydrolase (LTA4H)-proline-glycine-proline

13 roline (PGP) could be degraded by the enzyme leukotriene A4 hydrolase (LTA4H).

14 = 0.02), without significant improvement in leukotriene A4 hydrolase activity compared with placebo.

15 of the gluzincin tribe such as thermolysin, leukotriene A4 hydrolase relatives, and cowrins.

16 agen breakdown with prolyl endopeptidase and leukotriene A4 hydrolase serving as the enzymes responsi

17 ng inflammation-associated proteins, such as leukotriene A4 hydrolase.

18 dition, FLAP knockdown reduced conversion of leukotriene A4 to leukotriene C4 (LTC4), suggesting a ro

19 ole in the metabolism of arachidonic acid to leukotriene A4, the precursor to the potent pro-inflamma

20 Importantly, we find that neutrophil-derived leukotrienes aid the colonization of distant tissues by

21 Therefore, leukotriene and P2Y receptors utilize distinct membrane

22 PlGF exacerbates AHR and uniquely links the leukotriene and Th2 pathways in asthma.

23 protein inhibitor, prevents the synthesis of leukotrienes and 5-oxo-6,8,11,14-eicosatetraenoic acid (

24 Thus, cross-talk between leukotrienes and cholane steroids might converge on regu

25 h tick lipocalins that sequester monoamines, leukotrienes and fatty acids.

26 horsefly Tabanus yao, has been shown to bind leukotrienes and free fatty acids in vitro Therefore, he

27 farinae through the generation of cysteinyl leukotrienes and proinflammatory cytokines, respectively

28 nificant differences were found according to leukotriene antagonist exposure or whether NSAIDs were r

29 short course of doxycycline (3 weeks), or a leukotriene antagonist may be considered in patients wit

30 f selected asthma controller medication use (leukotriene antagonists and inhaled corticosteroids) on

31 Leukotriene antagonists improved nasal symptoms compared

32 c rhinitis and who then initiated the use of leukotriene antagonists were less likely to experience a

33 icating that pediatric patients treated with leukotriene antagonists were no more likely than those t

34 Our findings that cysteinyl leukotrienes are involved in regulating airway and lung

35 Cysteinyl leukotrienes are involved in the pathogenesis of postinf

36 Leukotrienes are mediators of the innate immune system a

37 Leukotrienes are proinflammatory lipid mediators that ha

38 cosanoids, including prostaglandins (PG) and leukotrienes, are lipid mediators derived from arachidon

39 ing resolvins, lipoxins, prostaglandins, and leukotrienes, as well as leukotriene to resolvin score r

40 Leukotriene B(4) (LTB(4)) receptor (BLT)1 is expressed o

41 in a relative narrow concentration range for leukotriene B4 (100-200 nm).

42 RvE1 binds to leukotriene B4 (BLT-1) on neutrophils and to ERV-1/ChemR

43 ly hypertensive rat (SHR) support a role for leukotriene B4 (LTB4 ), a potent chemoattractant involve

44 ly hypertensive rat (SHR) support a role for leukotriene B4 (LTB4 ), a potent chemoattractant involve

45 ease in the abundance of the proinflammatory leukotriene B4 (LTB4) and a corresponding decrease in th

46 mediated by signaling through the chemokine leukotriene B4 (LTB4) and its receptor LTB4R1.

47 Eicosanoids, such as leukotriene B4 (LTB4) and lipoxin A4 (LXA4), may play a

48 Leukotriene B4 (LTB4) contributes to many inflammatory d

49 The synthetic 13S,14S-epoxide inhibited leukotriene B4 (LTB4) formation by human leukotriene A4

50 ygenase (5LO) and its chemotactic metabolite leukotriene B4 (LTB4) in KSHV biology.

51 23 activates the synthesis and production of leukotriene B4 (LTB4) in myeloid cells, which modulate i

52 ion has demonstrated the mechanistic role of leukotriene B4 (LTB4) in the molecular pathogenesis of l

53 The pro-inflammatory mediator leukotriene B4 (LTB4) is implicated in the pathologies o

54 Leukotriene B4 (LTB4) is secreted by chemotactic neutrop

55 codynamic (PD) relationship based on ex vivo leukotriene B4 (LTB4) levels in dog.

56 ith palmitate, enhanced arginase 1 and lower leukotriene B4 (LTB4) levels were detected in macrophage

57 5-lipoxygenase (5-LO) activity and increased leukotriene B4 (LTB4) production have been implicated in

58 It has been reported that leukotriene B4 (LTB4) reduces the parasitic load of infe

59 e demonstrate that the lipid chemoattractant leukotriene B4 (LTB4) was efficacious at causing loss of

60 )-mediated C5 activation and also sequesters leukotriene B4 (LTB4) within an internal binding pocket.

61 They are the main source of leukotriene B4 (LTB4), a potent proinflammatory lipid me

62 Leukotriene B4 (LTB4), a proinflammatory mediator produc

63 ), and the ratio of SPMs to pro-inflammatory leukotriene B4 (LTB4), are significantly decreased in th

64 ), LXA4, and its counterregulatory compound, leukotriene B4 (LTB4), in patients with childhood asthma

65 X favors the biosynthesis of proinflammatory leukotriene B4 (LTB4), whereas, in theory, cytoplasmic 5

66 ion of inflammatory mediators, TNF-alpha and leukotriene B4 (LTB4), which are involved in parasite ki

67 d mediating general neutrophil chemotaxis is leukotriene B4 (LTB4).

68 l-leucyl-phenylalanine (fMLP) is mediated by leukotriene B4 (LTB4).

69 eutrophil production of a second eicosanoid, leukotriene B4 (LTB4).

70 Leukotriene B4 (LTB4R and LTB4R2) and cysteinyl leukotri

71 cosatetraenoic acid, cysteinyl leukotrienes, leukotriene B4 , 11-dehydro-thromboxane B2 , and prostag

72 that BLT2, a G protein-coupled receptor for leukotriene B4 and 12(S)-hydroxyheptadecatrienoic acid (

73 sor to the potent pro-inflammatory mediators leukotriene B4 and leukotriene C4 Studies with small mol

74 spect to inflammatory lipid mediators (i.e., leukotriene B4 and PGs) in omental adipose tissue from O

75 ediators including prostaglandin F2alpha and leukotriene B4 and pro-resolving mediators, including re

76 ectious exudates gave higher proinflammatory leukotriene B4 and procoagulating thromboxane B2, as wel

77 e included inflammation initiating mediators leukotriene B4 and prostaglandin E2 and pro-resolving me

78 Functionally, aortic Leukotriene B4 and Prostaglandin E2 levels correlated wi

79 n expansion of inflammatory lipid mediators, Leukotriene B4 and Prostaglandin E2, and a concomitant d

80 show that PGE2-G, but not PGE2-EA, inhibits leukotriene B4 biosynthesis, superoxide production, migr

81 Importantly, higher leukotriene B4 concentrations (>0.5 mum) and BLT2 agonis

82 Leukotriene B4 decreased in 4-aminopyridine and EPI grou

83 the release of high mobility group box 1 and leukotriene B4 from the epithelial cells and this releas

84 Two major G-protein-coupled receptors for leukotriene B4 have been identified: the high-affinity r

85 ic acid, 5-hydroxyeicosatetraenoic acid, and leukotriene B4 in particular could serve as potential bi

86 study, we explored the effect of the C5 and leukotriene B4 inhibitor Ornithodoros moubata complement

87 dimethyl fumarate, phosphodiesterase 4, and leukotriene B4 inhibitors in pemphigoid disorders, and c

88 Leukotriene B4 is a proinflammatory lipid mediator whose

89 mplement complex and significantly decreased leukotriene B4 levels in septic pigs.

90 Inhibition of leukotriene B4 or integrin rescues maturation and migrat

91 pofol binds to 5-lipoxygenase and attenuates leukotriene B4 production.

92 t 12-S-HHT, but not 16:4(n-3), functions via leukotriene B4 receptor 2 (BLT2).

93 strategy was applied to a typical GPCR, the leukotriene B4 receptor BLT2, reconstituted in a lipid b

94 this study, we investigated the roles of the leukotriene B4 receptor, BLT1, and CXCR3, the receptor f

95 e lung tumour burden and genetic deletion of leukotriene B4 receptor-1 (BLT1(-/-)) attenuates this in

96 Thus, the data show that the two leukotriene B4 receptors have opposing roles in the sens

97 mmunohistochemical analysis showed that both leukotriene B4 receptors were expressed in peripheral se

98 of this defect, as it leads to activation of leukotriene B4 signaling and induction of the alpha4beta

99 covers a previously undefined role of innate leukotriene B4 signaling as a gatekeeper of the hematopo

100 ve migration toward worms requires paracrine leukotriene B4 signaling between eosinophils.

101 hors show that changing miRNA biogenesis and leukotriene B4 signaling in mice modulates this switch i

102 Inactivation of leukotriene B4 signaling or genetic deficiency of PPARal

103 ic acid, 5-hydroxyeicosatetraenoic acid, and leukotriene B4), TRPV4 (5,6-epoxyeicosatrienoic acid [EE

104 on between rs174537 and the ratio of ARA/LA, leukotriene B4, and 5-HETE but no effect on levels of cy

105 EIA determined leukotriene B4, and ELISAs quantified TNF, IL-12 and IL-

106 Plasma levels of histamine, leukotriene B4, prostaglandin E2, prostaglandin F2, pH,

107 ctions in the generation of pro-inflammatory leukotriene B4, thus LTA4H exhibits opposing pro- and an

108 Accordingly, leukotriene B4-induced thermal hyperalgesia was mediated

109 the amniotic cavity reveals up-regulation of leukotriene B4.

110 ntly reduced without affecting the levels of leukotriene B4.

111 idase without affecting the bioproduction of leukotriene B4.

112 Phospholipase A2/5-lipoxygenase/leukotriene-B4 (PLA2/5-LOX/LTB4) axis is an important in

113 5-Lipoxygenase (5-LO) is the key enzyme in leukotriene biosynthesis.

114 and/or GM-CSF, namely, delayed apoptosis and leukotriene biosynthesis.

115 cretion and production of the lipid mediator leukotriene C(4) were unaffected.

116 t cell (MC) mediators (histamine, serotonin, leukotriene C(4), prostaglandin D2, and mouse mast cell

117 Orai3/Orai1 channels are gated by cytosolic leukotriene C4 (LTC4) and require STIM1 downstream LTC4

118 hat airway challenges with the parent CysLT, leukotriene C4 (LTC4), given in combination with low-dos

119 Cysteinyl leukotrienes (cysLTs), leukotriene C4 (LTC4), LTD4, and LTE4 are proinflammator

120 down reduced conversion of leukotriene A4 to leukotriene C4 (LTC4), suggesting a role for the activit

121 mation of the proinflammatory lipid mediator leukotriene C4 (LTC4).

122 axis to CCL19 that was restored by exogenous leukotriene C4 .

123 idant GSH and the pro-inflammatory cysteinyl leukotriene C4 have been identified as key physiological

124 Leukotriene C4 production by mast cells was not enhanced

125 Exogenous administration of leukotriene C4 restored trafficking of eosinophils to pa

126 ro-inflammatory mediators leukotriene B4 and leukotriene C4 Studies with small molecule inhibitors of

127 We asked whether mRNA levels of leukotriene C4 synthase (LTC4 S), a key regulator of leu

128 Leukotriene C4 synthase (LTC4S) catalyzes the formation

129 mitigated by deletions of either Cysltr2 or leukotriene C4 synthase (Ltc4s).

130 Deletion of leukotriene C4 synthase, the terminal enzyme needed to g

131 s were used to test chemotactic responses of leukotriene C4 synthase-deficient and control airway eos

132 -sensitized and ovalbumin aerosol-challenged leukotriene C4 synthase-deficient and control mice.

133 Leukotriene C4 synthase-deficient eosinophils exhibited

134 from distal alveolar lung was diminished in leukotriene C4 synthase-deficient mice compared with wil

135 sed retention of eosinophils in the lungs of leukotriene C4 synthase-deficient mice.

136 f eosinophils to paratracheal lymph nodes in leukotriene C4 synthase-deficient mice.

137 rophages, prostacyclin, prostaglandin E2 and leukotriene C4 were produced within minutes of C. albica

138 rved large conformational changes induced by leukotriene C4, explaining how substrate binding primes

139 pe I receptors by the physiological trigger, leukotriene C4.

140 secrete Th2-type cytokines (IL-4, IL-13) and leukotriene C4.

141 A with one of its physiological substrates, leukotriene C4.

142 activated receptor-2-dependent production of leukotrienes C4 associated with an overexpression of leu

143 Leukotriene-C4 synthase (LTC4S) generates LTC4 from arac

144 iene-synthesizing enzymes 5-lipoxygenase and leukotriene-C4-synthase.

145 F and the generation of histamine, cysteinyl-leukotrienes (cys-LTs) and prostaglandin D(2) (PGD(2) )

146 (FPR-2), triggered the release of cysteinyl leukotrienes (cys-LTs) from eosinophils.

147 ough arachidonic acid metabolites, cysteinyl leukotrienes (cys-LTs; leukotriene [LT] C4, LTD4, and LT

148 Tryptase and cysteinyl leukotriene (cysLT) levels were measured in nasal lavage

149 aluated as Ca2+ flux, secretion of cysteinyl leukotrienes (CysLT), and eosinophil-derived neurotoxin

150 rtner receptors (nucleotide P2Y12, cysteinyl-leukotriene CysLT1) to reconstitute the elusive pharmaco

151 Cysteinyl leukotrienes (cysLTs) are bronchoconstricting lipid medi

152 Prostaglandin D2 (PGD2) and cysteinyl leukotrienes (cysLTs) are lipid mediators derived from m

153 e E4 (LTE4) the most stable of the cysteinyl leukotrienes (cysLTs) binds poorly to classical type 1 (

154 Cysteinyl leukotrienes (CysLTs) contribute to asthma pathogenesis,

155 Cysteinyl leukotrienes (cysLTs) facilitate mucosal type 2 immunopa

156 and proinflammatory properties of cysteinyl leukotrienes (cysLTs) in allergic asthma mediate their e

157 irways, involves overproduction of cysteinyl leukotrienes (cysLTs), activation of airway mast cells (

158 Large amounts of cysteinyl leukotrienes (cysLTs), classically known as a slow react

159 Cysteinyl leukotrienes (cysLTs), including leukotriene (LT) C4, LT

160 Cysteinyl leukotrienes (cysLTs), leukotriene C4 (LTC4), LTD4, and

161 r whether lipid mediators, such as cysteinyl leukotrienes (CysLTs), which are present in asthma, coul

162 e formation of eicosanoids such as cysteinyl leukotrienes (CysLTs).

163 f both producing and responding to cysteinyl leukotrienes (CystLTs), allowing for the killing of targ

164 sured in purified lung ILC2s stimulated with leukotriene D(4) (LTD(4)) in the presence or absence of

165 sputum eosinophilia correlated with a higher leukotriene D4 (LTD4 ) and leukotriene E4 (LTE4 ) concen

166 In vitro stimulation with leukotriene D4 increased iNOS mRNA levels and NO product

167 red that Galphaq-linked prostaglandin E2 and leukotriene D4 receptors also regulate APP expression.

168 to nematodes, yet are able to undergo robust leukotriene-dependent migration toward IgG-coated beads.

169 report that uracil nucleotides and cysteinyl leukotrienes do not activate human, mouse, or rat GPR17

170 Inactive leukotrienes docked onto a portion of the site, probably

171 nt of the release of histamine and cysteinyl leukotrienes documented that this bronchoprotective acti

172 ng peripheral airway obstruction and urinary leukotriene E(4) levels indicating cysteinyl leukotriene

173 ICS step-up therapy, whereas higher urinary leukotriene E(4) levels were marginally (P = .053) relat

174 There were no changes in leukotriene E(4) or 9alpha,11beta-PGF(2) levels after AD

175 ted with a higher leukotriene D4 (LTD4 ) and leukotriene E4 (LTE4 ) concentrations.

176 Leukotriene E4 (LTE4) the most stable of the cysteinyl l

177 lia, and increased concentrations of urinary leukotriene E4 (LTE4).

178 nation of PGD2 and cysLTs (notably cysteinyl leukotriene E4 [LTE4]) enhances TH2 cytokine production.

179 correlated with basal urinary levels of both leukotriene E4 and PGD-M.

180 Levels of urinary leukotriene E4 and the stable plasma prostaglandin (PG)

181 d, and quantification of PGD2 metabolite and leukotriene E4 levels was done by using ELISA.

182 reported outcomes and a reduction in urinary leukotriene E4 levels were observed during roflumilast p

183 ant increases in urinary PGD2 metabolite and leukotriene E4 levels.

184 Levels of CysLT1R, CysLT2R, and candidate leukotriene E4 receptor P2Y12 mRNAs were increased in IL

185 ysis showed that five biomarkers (20-Hydroxy-leukotriene E4, Lysopc(20:4), 5-methoxytryptamine, Endom

186 ecursors and selectively increased cysteinyl leukotriene formation by mast cells in a manner that was

187 Genetic or pharmacological inhibition of the leukotriene-generating enzyme arachidonate 5-lipoxygenas

188 Increased production of leukotrienes has been associated with periodontal diseas

189 Increased production of leukotrienes has been associated with periodontal diseas

190 Leukotrienes have been explored as therapeutic targets f

191 f a highly influential FADS SNP, rs174537 on leukotriene, HETE, prostaglandin, and thromboxane biosyn

192 e LTC4, the parent compound of the cysteinyl leukotrienes, important mediators of asthma.

193 thophysiology of lymphedema, and the role of leukotrienes in lymphedema pathogenesis.

194 We investigated roles of cysteinyl leukotrienes in mediating eosinophil trafficking from lu

195 viously unrecognized roles for the cysteinyl leukotrienes in regulating the pulmonary trafficking of

196 icited IL-6, IL-23, TNF-alpha, and cysteinyl leukotrienes in the lung.

197 ) was demonstrated using a bespoke cysteinyl leukotriene induced rodent model.

198 leukotriene E(4) levels indicating cysteinyl leukotriene inflammation can differentiate LABA step-up

199 differences in the effectiveness of certain leukotriene inhibitors and link the differences in respo

200 ales, but sex as a factor in the response to leukotriene inhibitors has not been fully explored.

201 gets for these diseases and others; however, leukotriene inhibitors have had limited success in the c

202 to consideration in the future evaluation of leukotriene inhibitors to treat disease.

203 -,15-hydroxyeicosatetraenoic acid, cysteinyl leukotrienes, leukotriene B4 , 11-dehydro-thromboxane B2

204 model, we observed increased AHR and higher leukotriene levels that were abrogated by anti-PlGF Ab o

205 Leukotriene (LT) A4 hydrolase/aminopeptidase (LTA4H) is

206 Human leukotriene (LT) A4 hydrolase/aminopeptidase (LTA4H) is

207 The leukotriene (LT) and wingless/integrase (Wnt) pathways h

208 Because leukotriene (LT) B(4) has been shown to suppress intrace

209 We have shown that leukotriene (LT) B4 (LTB4) positively regulates macropha

210 5-Lipoxygenase (5LO) is a key enzyme in leukotriene (LT) biosynthesis.

211 Leukotriene (LT) C4 synthase (LTC4S) catalyzes the conju

212 Cysteinyl leukotrienes (cysLTs), including leukotriene (LT) C4, LTD4, and LTE4, are metabolites of

213 This was associated with an ablation of leukotriene (LT) production, consistent with production

214 Because fMLP-stimulated neutrophils produce leukotriene (LT)B4, we examined the effect of propofol o

215 ary tetranor prostaglandin (PG)D2 (PGDM) and leukotriene (LT)E4 , induced sputum fluid LTB4 , LTE4 ,

216 ct and is characterized by overproduction of leukotrienes (LT) and large numbers of circulating granu

217 etabolites, cysteinyl leukotrienes (cys-LTs; leukotriene [LT] C4, LTD4, and LTE4), and prostaglandin

218 Leukotrienes (LTA4, LTB4, LTC4, LTD4, and LTE4) are infl

219 ame enzymes contributing to the synthesis of leukotrienes LTB4 and LTC4, mediators of inflammation an

220 Proinflammatory leukotrienes (LTs) are produced by 5-lipoxygenase (5-LO)

221 Leukotrienes (LTs) are proinflammatory lipid mediators f

222 undant NFAT-dependent role for lipid-derived leukotrienes (LTs) in the activation of lung ILC2s.

223 exhaled breath condensate (EBC) lipoxin and leukotriene measurements can noninvasively characterize

224 re are noted differences in the incidence of leukotriene-mediated diseases in males and females, but

225 th their classic substrates in the cysteinyl leukotriene metabolome.

226 PEF data from 493 participants in the LOCCS (Leukotriene Modifier Corticosteroid or Corticosteroid-Sa

227 Increased use of ICSs and leukotriene modifiers was observed just after the regula

228 ng products, inhaled corticosteroids (ICSs), leukotriene modifiers, short-acting beta2-agonists, oral

229 ifferentiating at least five closely related leukotrienes partially coeluting and (almost) unresolvab

230 Plgf-/- mice treated with leukotrienes phenocopied the WT response to allergen exp

231 by a surge in bronchoconstrictory cysteinyl leukotrienes produced at the expense of LTB4 in AERD sub

232 PGs, produced by cyclooxygenases (COX), and leukotrienes, produced by 5-lipoxygenase (5-LO) have bee

233 data reveal that 5-LO, which is required for leukotriene production and subsequent T cell recruitment

234 nematode-derived signals can directly induce leukotriene production by eosinophils and that leukotrie

235 ene C4 synthase (LTC4 S), a key regulator of leukotriene production, could serve as a marker for EoE.

236 rotein in BMDMs was observed, the absence of leukotrienes production reflected an impairment in 5-LO

237 Our data show that LTB4, via its receptor B leukotriene receptor 1 (BLT1) and Galphai signaling, inc

238 B4 act through activation of its receptor, B leukotriene receptor 1 (BLT1).

239 rthermore, LTD4 plus PGE2, through cysteinyl leukotriene receptor 1 (CysLT1R) and E-prostanoid recept

240 thma pathogenesis, in part through cysteinyl leukotriene receptor 1 (CysLT1R).

241 " neutrophil subset that expressed cysteinyl leukotriene receptor 1 (CysLTR1) and produced TNF, CCL2,

242 and montelukast, an antagonist of cysteinyl leukotriene receptor 1.

243 d a recurrent mutation in CYSLTR2 (cysteinyl leukotriene receptor 2) encoding a p.Leu129Gln substitut

244 stain cytoplasmic Ca(2+) signaling following leukotriene receptor activation both by refilling the Ca

245 fter rundown of the Ca(2+) signals following leukotriene receptor activation, stimulation of P2Y rece

246 e as a dualistic uracil nucleotide/cysteinyl leukotriene receptor and by others as inactive toward th

247 ccelerated homologous desensitization of the leukotriene receptor and thereby terminated the oscillat

248 steroid (ICS step-up therapy) or addition of leukotriene receptor antagonist (LTRA step-up therapy) o

249 ment with ICSs alone (n = 1758) or ICSs plus leukotriene receptor antagonist (LTRAs; n = 354) or ICSs

250 ge in FEV1 in the Characterizing Response to Leukotriene Receptor Antagonist and Inhaled Corticostero

251 ium Respimat added to ICSs with or without a leukotriene receptor antagonist in a phase III trial in

252 nist, long-acting muscarinic antagonist, and leukotriene receptor antagonist was hospitalized with a

253 vide benefit if combined with montelukast, a leukotriene receptor antagonist, in patients whose sympt

254 he effectiveness of montelukast, a cysteinyl leukotriene receptor antagonist, in the treatment of pos

255 ecommend an intranasal corticosteroid over a leukotriene receptor antagonist.

256 to ICS background therapy, with or without a leukotriene receptor antagonist; long-acting beta2-agoni

257 roids (21.5%; 95% CI: 20.7%-22.3%; p<0.001), leukotriene receptor antagonists (13.4%; 95% CI: 12.9%-1

258 Long-acting beta2-agonists (LABA) and leukotriene receptor antagonists (LTRA) are two principa

259 daily inhaled corticosteroids (ICSs), daily leukotriene receptor antagonists, and as-needed ICS trea

260 s, long-acting inhaled beta2-stimulants, and leukotriene receptor antagonists, increased year after y

261 ticosteroids, long-acting beta-agonists, and leukotriene receptor antagonists.

262 mple, H1- and H2-antihistamines or cysteinyl leukotriene receptor antagonists.

263 ay disease include the use of muscarinic and leukotriene receptor antagonists; however, these pharmac

264 s the way for future clinical translation of leukotriene receptor inhibition for the treatment of dem

265 This work illustrates that inhibition of leukotriene receptor signalling might represent a safe a

266 enes C4 associated with an overexpression of leukotrienes receptor CysLTR1 by asthmatic BSM cells in

267 Finally, leukotrienes receptor expression was assessed in vitro b

268 Leukotriene-receptor antagonists (LTRAs) are recommended

269 Leukotriene-receptor antagonists as monotherapy improved

270 Leukotriene-receptor antagonists either as monotherapy o

271 kotriene B4 (LTB4R and LTB4R2) and cysteinyl leukotriene receptors (CYSLTR1 and CYSLTR2) contribute t

272 genic small molecule antagonist of cysteinyl leukotriene receptors 1 and 2 (CysLT1 and CysLT2).

273 get VEGF receptors but antagonizes cysteinyl leukotriene receptors 1 and 2 (CysLT1-2) at micromolar I

274 The expression of leukotriene receptors was deregulated in esophageal squa

275 ajor findings were: 1) protein levels of all leukotriene receptors were significantly increased in es

276 ing to replenish the PIP2 pool accessible to leukotriene receptors, ostensibly through control of PIP

277 a marketed anti-asthmatic drug antagonizing leukotriene receptors, reduces neuroinflammation, elevat

278 actor that acts on plasma membrane cysteinyl leukotriene receptors.

279 sion, T-cell death, and eosinophil cysteinyl leukotriene release.

280 calculated for each patient, and posttrauma leukotriene score to resolvin score ratios were signific

281 higher resolvin scores (p < 0.001) and lower leukotriene scores (p < 0.001).

282 ukotriene production by eosinophils and that leukotriene signaling is a major contributor to nematode

283 However, mice deficient in leukotriene signaling show markedly attenuated eosinophi

284 Using pharmacological inhibitors of leukotriene synthesis, our findings reveal an LTB4-drive

285 edin-B (NMB), nerve growth factor (NGF), and leukotriene-synthesis enzymes (ALOX5, ALOX5AP, and LTA4H

286 expression of the Th2 cytokine IL-13 and the leukotriene-synthesizing enzymes 5-lipoxygenase and leuk

287 osinophils, and macrophages, creating a PlGF/leukotriene/Th2-response positive feedback loop.

288 oids and docosanoids such as prostaglandins, leukotrienes, thromboxanes, isoprostanes, resolvins, hyd

289 The de novo synthesis of cysteinyl leukotrienes, TNFalpha, CXCL8, CCL2, CCL3, and CCL4, was

290 prostaglandins, and leukotrienes, as well as leukotriene to resolvin score ratios.

291 tributions of mediators other than cysteinyl leukotrienes to aspirin reactions and to the therapeutic

292 mic Ca(2+) oscillations induced by cysteinyl leukotriene type I receptor activation run down when cel

293 be evoked by modest activation of cysteinyl leukotriene type I receptors by the physiological trigge

294 The cysteinyl leukotriene type I receptors desensitize through negativ

295 Leukotrienes were applied at 0.1 nm-10 mum to either lea

296 nzyme of the biosynthesis of proinflammatory leukotrienes were in the range of the approved drug zile

297 poxygenase (5-LO) is key in the synthesis of leukotrienes, which are potent proinflammatory lipid med

298 LTC4 is the parent molecule of the cysteinyl leukotrienes, which are recognized for their pathogenic

299 f bioactive mediators, such as histamine and leukotrienes, which initiate allergic reactions.

300 from an imbalance between prostaglandins and leukotrienes, which may serve as targets for future host